{"id":"W2947559705","doi":"10.1200/jco.2019.37.15_suppl.3095","title":"A phase I/II first-in-human trial of oral SRA737 (a Chk1 inhibitor) given in combination with low-dose gemcitabine in subjects with advanced cancer.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"ca_institutions":"Sierra Wireless (Canada)","funders":"","keywords":"Gemcitabine; Medicine; Tolerability; Pharmacodynamics; Pharmacokinetics; Cancer; Bioavailability; Cervical cancer; Internal medicine; Pharmacology; Ovarian cancer; CHEK1; Oncology; Adverse effect; Cell cycle; Cell cycle checkpoint","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001782226,0.0002157672,0.002174841,0.0004375934,0.00002073931,0.000003593004,0.0001723359,0.0002655928,0.00009858367],"category_scores_gemma":[0.0005189673,0.0001514707,0.0001502075,0.0005438652,0.0002603967,0.0003851409,0.000041749,0.001180599,0.000001656409],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006432855,"about_ca_system_score_gemma":0.001836986,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002555614,"about_ca_topic_score_gemma":0.006109146,"domain_scores_codex":[0.9962575,0.0002928468,0.00234306,0.0002900143,0.0004780111,0.0003385318],"domain_scores_gemma":[0.9964205,0.000752406,0.002042897,0.0002272353,0.0003768366,0.0001801187],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.675197,0.02051717,0.1673173,0.0001751364,0.0001789606,0.0008494177,0.0007322447,0.00185759,0.002474961,0.0001103313,0.00002602533,0.1305639],"study_design_scores_gemma":[0.6581233,0.1772577,0.1579805,0.001714775,0.00008807395,0.00009319533,0.0002941782,0.0001518019,0.0006259621,0.0003207408,0.003166096,0.0001837305],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9935367,0.0002793826,0.00003545558,0.004215499,0.0005910384,0.001061638,0.00000372557,0.000007011086,0.0002696151],"genre_scores_gemma":[0.9976388,0.0001778834,0.001409155,0.0003256609,0.0002967284,0.00003528564,0.000004468606,0.00003121404,0.00008086199],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1567405,"threshold_uncertainty_score":0.6176796,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04307739164022831,"score_gpt":0.4383624701805542,"score_spread":0.3952850785403259,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}